FDA has approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.
Read more: FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors